NCT06169982View on ClinicalTrials.gov

A Multiple Dose Study of LY3209590 in Participants With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

December 7, 2023

Primary Completion Date

July 18, 2024

Study Completion Date

July 18, 2024

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

LY3209590

Administered SC

Trial Locations (1)

41460

Profil Institut für Stoffwechselforschung, Neuss

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT06169982 - A Multiple Dose Study of LY3209590 in Participants With Type 2 Diabetes | Biotech Hunter | Biotech Hunter